Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.59 |
| ▸ | DRD2 | P14416 | 4/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175448 | 0.92 | MGLL (0.60) | HTR1ADRD2MGLLABCB1PTGER1 | |
| SCHEMBL5658385 | 0.88 | CA1 (0.49) | HTR1ADRD2MGLLABCB1 | |
| SCHEMBL24041898 | 0.88 | ABCB1 (0.64) | HTR1ADRD2MGLLABCB1ABCG2 | |
| SCHEMBL24041895 | 0.87 | HTR1A (0.46) | HTR1ADRD2MGLLABCB1PTGER1 | |
| SCHEMBL4851116 | 0.86 | HTR1A (0.56) | HTR1ADRD2MGLLABCB1PTGER1 | |
| SCHEMBL772767 | 0.83 | HTR1A (0.51) | HTR1AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL4860922 | 0.83 | L3MBTL1 (0.56) | GAAMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL9117894 | 0.82 | HTR1A (0.52) | HTR1ADRD2MGLLABCB1PTGER1 | |
| SCHEMBL5657713 | 0.82 | L3MBTL1 (0.46) | MAPTMAPK1L3MBTL1 | |
| SCHEMBL9270709 | 0.82 | HTR1A (0.50) | HTR1AMGLLMAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436445-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3193881-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3436445-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2019-02-06 | — | — | EP | disclosed |
| US-10174003-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174003-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10071984-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9896436-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2016044342-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071984-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | HTR1A 3100/4885DRD2 4637/4885MGLL 1669/4885 |
| US-10174003-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | HTR1A 3100/4885DRD2 4637/4885MGLL 1669/4885 |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | HTR1A 3100/4885DRD2 4637/4885MGLL 1669/4885 |
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 79/4885DRD2 402/4885MGLL 673/4885 |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | HTR1A 3100/4885DRD2 4637/4885MGLL 1669/4885 |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | HTR1A 3100/4885DRD2 4637/4885MGLL 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.